EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses

Oliver FitzGerald iD, Dafna D Gladman iD, Philip J Mease iD, Christopher Ritchlin iD, Josef S Smolen iD, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42921 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Oliver FitzGerald und 9 weiteren Autor:innen. Beteiligte Einrichtung: University College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Biomarkers, Interleukin-17. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our objective was to evaluate the association of serum biomarkers with baseline psoriatic arthritis (PsA) disease activity, pharmacodynamic effects of deucravacitinib on biomarker levels, and the relationship between biomarkers and clinical responses to deucravacitinib.

Methods

The phase 2 trial ( ClinicalTrials.gov identifier: NCT03881059) randomly assigned 203 patients with PsA 1:1:1 to placebo, deucravacitinib at 6 mg once daily (QD), or deucravacitinib at 12 mg QD. Serum biomarkers associated with the interleukin 23 (IL‐23) pathway (IL‐17A, β‐defensin [BD‐2], and IL‐19), type I interferon pathway, inflammation, and collagen matrix turnover were measured by immunoassay. Clinical responses (≥75% improvement from baseline in the Psoriasis Area and Severity Index [PASI75] and ≥20% improvement from baseline in American College of Rheumatology criteria [ACR20] responses) were measured at week 16. Hematologic variables were also assessed.

Results

IL‐17A, BD‐2, and IL‐19 had a modest association with PASI scores (r = 0.4, r = 0.56, and r = 0.5, respectively) at baseline. In deucravacitinib groups, IL‐17A, BD‐2, IL‐19, C‐X‐C motif ligand 9 (CXCL9), CXCL10, C‐reactive protein, matrix metalloproteinase 3, and collagen type 4 degradation marker levels were significantly reduced at week 16 versus baseline ( P < 0.01); higher levels of IL‐23 pathway–associated biomarkers predicted higher PASI75 and ACR20 response rates in deucravacitinib‐treated patients. Significantly higher PASI75 response rates were seen in patients with high baseline IL‐17A (odds ratio 15.76) and BD‐2 levels (odds ratio 15.41) versus low baseline IL‐17A and BD‐2 levels. Changes in hematologic variables that are characteristic of JAK inhibition were not observed with deucravacitinib.

Conclusion

Deucravacitinib significantly impacted biomarkers associated with Tyk2 signaling pathways of key inflammatory cytokines, including IL‐23 and type I interferon, and those related to collagen matrix turnover. These biomarkers may predict treatment responses to deucravacitinib. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticBiomarkersInterleukin-17HumansMaleFemaleMiddle AgedAdultTreatment Outcomebeta-DefensinsSeverity of Illness IndexMatrix Metalloproteinase 3Double-Blind MethodChemokine CXCL10Interleukin-23

Substanzen

BiomarkersInterleukin-17beta-DefensinsMatrix Metalloproteinase 3IL17A protein, humanChemokine CXCL10Interleukin-23CXCL10 protein, human

Autor:innen und Institutionen

  • University College Dublin, Dublin, Ireland.
  • University of Toronto, Toronto, Ontario, Canada.
  • Swedish Medical Center, Seattle, Washington.
  • University of Rochester Medical Center, Rochester, New York.
  • Medical University of Vienna and Hietzing Hospital, Vienna, Austria.
  • Bristol Myers Squibb, Princeton, New Jersey.

ORCID-Profile: Oliver FitzGerald, Dafna D Gladman, Philip J Mease, Christopher Ritchlin, Josef S Smolen

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

FitzGerald, O., Gladman, D. D., Mease, P. J., Ritchlin, C., Smolen, J. S., Gao, L., Hu, Y., Nowak, M., Banerjee, S., & Catlett, I. (2024). Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & Rheumatology. https://doi.org/10.1002/art.42921

Vancouver

FitzGerald O, Gladman DD, Mease PJ, Ritchlin C, Smolen JS, Gao L, et al. Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & Rheumatology. 2024. doi:10.1002/art.42921

BibTeX
@article{FitzGerald2024,
  author = {FitzGerald, Oliver and Gladman, Dafna D and Mease, Philip J and Ritchlin, Christopher and Smolen, Josef S and Gao, Lu and Hu, Yanhua and Nowak, Miroslawa and Banerjee, Subhashis and Catlett, Ian},
  title = {Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42921}
}
Kostenlos starten →